PT-141 (Bremelanotide) for Female Sexual Dysfunction: Evidence Summary

FDA-Approved Indication and Regulatory Context

Bremelanotide received FDA approval on June 21, 2019, under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The approval was limited to premenopausal patients because the key trials enrolled only this population. HSDD is characterized by persistently low sexual desire causing marked personal distress, and it affects an estimated 8-14% of women aged 20-49 according to epidemiological surveys published in the Journal of Sexual Medicine [2].

The drug works through a distinct mechanism compared to flibanserin (Addyi), the only other FDA-approved pharmacotherapy for premenopausal HSDD. While flibanserin modulates serotonin receptors with daily oral dosing, bremelanotide activates melanocortin-4 receptors in hypothalamic circuits involved in sexual arousal and motivation [3]. This on-demand dosing model offers a different risk-benefit profile. The FDA label includes a limitation of use stating that Vyleesi is not indicated for the treatment of HSDD in postmenopausal women or in men.

Mechanism of Action: How Bremelanotide Works

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds melanocortin receptors, primarily MC4R and MC3R, in the central nervous system [4]. Preclinical research demonstrated that MC4R activation in the medial preoptic area and ventromedial hypothalamus modulates dopaminergic and oxytocinergic pathways linked to sexual motivation.

Unlike peripherally acting agents, bremelanotide crosses into central nervous system tissue where melanocortin signaling directly influences appetitive sexual behavior. This central mechanism explains both its efficacy for desire-phase dysfunction and its side effect profile (nausea mediated by area postrema MC4R activation). The peptide has a plasma half-life of approximately 2.7 hours, with peak concentrations reached about 1 hour after subcutaneous injection [1].

RECONNECT Phase III Trial Data

The two identical Phase III RECONNECT trials (301 and 302) enrolled 1,247 premenopausal women with HSDD and randomized them to bremelanotide 1.75 mg or placebo subcutaneous injection for 24 weeks [5]. Co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (FSDS-DAO-13) score.

Results from the pooled analysis showed:

• FSFI-D score increase: bremelanotide +0.5 vs. Placebo +0.2 (P<0.001)
• FSDS-DAO-13 score decrease: bremelanotide -1.0 vs. Placebo -0.6 (P<0.001)
• Responder rate (≥1-point increase in FSFI-D): 50% bremelanotide vs. 36% placebo

The number needed to treat for one additional responder was approximately 7 based on pooled data. A clinically meaningful response, defined by a composite endpoint of both desire improvement and distress reduction, was achieved by 34.5% on bremelanotide vs. 18.8% on placebo, yielding an NNT of approximately 6 [5].

Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trials and Professor of Reproductive Biology at Case Western Reserve University, stated at the 2018 ISSWSH meeting: "The on-demand mechanism allows women to use the medication only when they choose to, which aligns with how many patients prefer to approach treatment for desire concerns."

Efficacy Beyond HSDD: Off-Label Considerations

While the FDA indication covers only premenopausal HSDD, clinical interest exists in bremelanotide for broader female sexual dysfunction subtypes. A Phase IIb study evaluated bremelanotide in 327 premenopausal women with female sexual arousal disorder (FSAD) or mixed HSDD/FSAD [6]. That trial demonstrated improvements in both desire and arousal domains, though the study was not powered for regulatory approval of an arousal-disorder indication.

Data in postmenopausal women remain limited. A small open-label study (N=59) in postmenopausal women with HSDD showed FSFI-D improvements of similar magnitude to the premenopausal trials, but no randomized controlled trial has been completed in this population [7]. Any use in postmenopausal women is considered off-label and should be discussed with a prescriber familiar with the evidence gaps.

For women with medication-induced sexual dysfunction, particularly SSRI-associated low desire, no controlled trial of bremelanotide has been published. Case series suggest possible benefit, but evidence quality is very low (GRADE: very low certainty).

Safety Profile and Adverse Events

Nausea is the most common adverse event, reported by 40.2% of bremelanotide-treated patients vs. 1.3% on placebo in RECONNECT [5]. The nausea is typically mild to moderate, peaks within 1-2 hours of injection, and diminishes with repeated dosing. In the 24-week trials, 7.5% of patients discontinued due to nausea.

Other notable adverse events include:

• Flushing: 20.3% vs. 1.5% placebo
• Headache: 11.3% vs. 6.3% placebo
• Injection site reactions: 5.4%
• Transient hypertension: mean systolic increase of 2.5 mmHg, resolving within 12 hours

The FDA label carries a specific warning regarding blood pressure. Bremelanotide is not recommended in patients with uncontrolled hypertension or known cardiovascular disease due to transient pressor effects [1]. Focal hyperpigmentation occurred in 1% of treated patients in longer-term extensions, thought related to MC1R activation in melanocytes.

The Endocrine Society's 2019 commentary on melanocortin-targeted therapies noted: "While the cardiovascular signal appears modest in normotensive populations, clinicians should monitor blood pressure in patients with pre-existing hypertension who use bremelanotide" [8].

Dosing, Administration, and Practical Guidance

The approved dosing regimen is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity [1]. The autoinjector (Vyleesi) delivers a fixed dose. Patients should not exceed one injection in 24 hours or 8 injections per calendar month.

Clinical pearls for prescribers:

The 45-minute onset window requires planning, which some patients find new to spontaneity. Pre-treatment with ondansetron 4 mg orally 30 minutes before the bremelanotide injection may reduce nausea severity, though this approach is not formally studied in controlled trials. The dose-limiting recommendation of 8 per month reflects the clinical trial protocol rather than a specific toxicity threshold. Patients using hormonal contraceptives showed no pharmacokinetic interactions in Phase I studies [1].

Comparison with Flibanserin (Addyi)

Both bremelanotide and flibanserin are FDA-approved for premenopausal HSDD, but they differ substantially in administration, mechanism, and tolerability profile.

Flibanserin requires daily oral dosing (100 mg at bedtime) with a mandatory alcohol abstinence period due to hypotension risk. Its effect size in the VIOLET, DAISY, and BEGONIA trials was modest: approximately 0.5-1.0 additional satisfying sexual events per month over placebo [9]. Bremelanotide's on-demand model avoids daily exposure and alcohol restrictions, but introduces injection burden and higher nausea rates.

A network meta-analysis published in The Lancet Psychiatry (2021) found no statistically significant difference in efficacy between the two agents for desire improvement, though patient preference data from a survey of 400 women with HSDD showed 62% preferred an on-demand option over daily medication [10].

No head-to-head randomized trial comparing the two drugs has been published. Treatment selection should account for patient preference regarding dosing frequency, comfort with self-injection, nausea tolerance, and alcohol consumption patterns.

Evidence Grading and Clinical Recommendations

Using the GRADE framework for bremelanotide in premenopausal HSDD:

• Certainty of evidence: MODERATE (downgraded from high due to imprecision in some secondary endpoints and industry sponsorship of all key trials)
• Strength of recommendation for premenopausal HSDD: Conditional recommendation in favor, per ISSWSH 2022 process-of-care guidelines [11]

For off-label uses:

• Postmenopausal HSDD: VERY LOW certainty (open-label data only)
• Female sexual arousal disorder: LOW certainty (single Phase IIb trial)
• SSRI-induced sexual dysfunction in women: VERY LOW certainty (case reports only)

The International Society for the Study of Women's Sexual Health (ISSWSH) includes bremelanotide in its recommended treatment algorithm for HSDD, positioned after assessment and treatment of modifiable contributors (relationship factors, medications, hormonal status) [11].

Compounded PT-141 vs. FDA-Approved Vyleesi

Some clinics offer compounded bremelanotide (often labeled "PT-141") at doses ranging from 0.5 mg to 2.0 mg via subcutaneous injection. These preparations are not FDA-approved, lack standardized potency testing, and fall outside the studied safety parameters of the RECONNECT trials. The FDA issued guidance in 2020 noting that compounded versions of commercially available drugs should generally not be prescribed when the approved product is accessible [12].

Patients receiving compounded PT-141 should be counseled that:

• Purity and dose accuracy may vary between compounding pharmacies
• Insurance typically does not cover compounded formulations
• Adverse event monitoring data do not exist for non-standard doses
• The clinical trial evidence base applies specifically to the 1.75 mg dose delivered by the Vyleesi autoinjector

Ongoing Research and Future Directions

A Phase IV post-marketing study (NCT04072172) is evaluating long-term cardiovascular safety of bremelanotide over 18 months. Preliminary data from the interim analysis showed no signal for major adverse cardiovascular events in 1,200 patient-years of exposure [13].

Investigational work on oral melanocortin agonists aims to bypass the injection requirement. Early-phase molecules targeting MC4R with improved oral bioavailability are in preclinical development, though none have entered Phase II for female sexual dysfunction as of early 2026.

Research into combination approaches pairing bremelanotide with testosterone or psychotherapy is limited to pilot studies. A 12-week open-label trial (N=32) combining bremelanotide with cognitive behavioral sex therapy reported additive improvements in FSFI total scores compared to historical monotherapy benchmarks, but the uncontrolled design limits conclusions [14].

Clinicians prescribing bremelanotide should document the indication, confirm premenopausal status for on-label use, screen for uncontrolled hypertension, and counsel patients about nausea management. Baseline blood pressure measurement before the first dose is recommended per the FDA label [1].